

Special Issue

COVID-19 and Molecular Genetics

Message from the Guest Editors

With 31,926,175 confirmed cases; 977,357 deaths (3.1%); and 22,004,598 recovered (68.9%) (Sept 24, 2020), COVID-19 is currently the number one challenge for human health worldwide. The COVID-19 pandemic wave has generated many urgent questions about the origin, trajectory, tissue/host variance, and the different clinical manifestations of the causative agent SARS-CoV-2. This Special Issue of *Genes* will focus on examining genetic/genomic variations, pathogenic mechanisms, clinical manifestations, and epidemiological and ethical aspects of the host. Research papers addressing the identification of genetic and epigenetic factors that confer susceptibility or resistance to viral infections and increase the risk of life-threatening complications will be welcomed. The overall objective of the Special Issue is to contribute to scientific knowledge through the identification of actionable biomarkers to improve diagnosis and management, predict clinical and immunological outcomes, and accelerate the development of new treatments.

Guest Editors

Prof. Dr. Giuseppe Novelli

Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, 00133 Rome, Italy

Prof. Dr. Michela Biancolella

Department of Biology, Tor Vergata University of Rome, 00133 Rome, Italy

Deadline for manuscript submissions

closed (20 May 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/62139

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))